TOP
STORY

A cancer treatment already approved for use in certain types of cancer has been found to block cell growth in a common form of lung cancer for which there is currently no specific treatment available. The authors suggest that a large number of patients could benefit from this treatment – a second generation EGFR inhibitor – if used in combination with additional therapies. [Press release from the University of Glasgow discussing online prepublication in Science Translational Medicine]
Press Release | Abstract

Ozone produces pulmonary inflammation that is highly variable between individuals; but reproducible within a single individual, indicating undefined susceptibility factors. Studying inter-individual variability is difficult with common experimental models, thus the authors used primary human bronchial epithelial cells collected from many different donors. [Sci Rep]
Full Article

The authors investigated the effect of stimulation of human bronchial epithelial cells by arterial traffic ambient PM2.5 and wood smoke PM2.5 on the expression of lncRNAs in order to find new therapeutic targets for treatment of chronic obstructive pulmonary disease. [Biosci Rep]
Abstract | Full Article

Researchers evaluated the mRNA levels from caspase-3 and BCL-2 genes and DNA fragmentation in lung tissue from Wistar rats affected by acute lung injury and subjected to photobiomodulation by exposure to a low power infrared laser. [Photochem Photobiol Sci]
Abstract

Investigators found that KAP1 interacts with c-Raf. Knocking out KAP1 decreased c-Raf phosphorylation at serine 259 and increased its phosphorylation at serine 338, which activated MEK and ERK. [Mol Carcinog]
Abstract

A growing number of tissue engineering approaches are exploring the potential to generate lung tissue ex vivo for transplantation. Both biologically derived and manufactured scaffolds seeded with cells and grown ex vivo have been explored in pre-clinical studies, with the eventual goal of generating functional pulmonary tissue for transplantation. [Eur Respir J]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the pulmonary cell research field.

Bristol-Myers Squibb Company announced that the China National Drug Administration has approved Opdivo for the treatment of locally advanced or metastatic NSCLC after prior platinum-based chemotherapy in adult patients without EGFR or ALK genomic tumor aberrations. [Bristol-Myers Squibb Company]
Press Release

Vertex Pharmaceuticals Incorporated announced that ORKAMBI®, the first medicine to treat the underlying cause of cystic fibrosis in people with two copies of the F508del mutation, ages six and older, will be reimbursed in Sweden after concluding the three-party negotiations with TLV and the county councils. [Vertex Pharmaceuticals Incorporated]
Press Release

The National Science Foundation (NSF) in Alexandria, Virginia, is in line for a budget increase of 4% to 5% next year. That assessment is based on bills approved recently by the spending committees in both chambers of Congress. Lawmakers have also signaled support for growing the account that NSF uses to build major new scientific facilities. [ScienceInsider]
Editorial

The medical research grant system in the United States, run through the National Institutes of Health, is intended to fund work that spurs innovation and fosters research careers. In many ways, it may be failing. [The New York Times]
Editorial

A draft bill released by a House of Representatives spending panel would give the National Institutes of Health (NIH) in Bethesda, Maryland, a $1.25 billion raise in 2019, to $38.3 billion. That is 3% more than this year’s level and $4.1 billion more than President Donald Trump’s administration had requested. [ScienceInsider]
Editorial